All In Biotech

Drug Trial Radar · NCT04179175

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 702 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

702

Actual

Start

Mar 18, 2020

Primary completion

May 26, 2023

Study completion Jul 15, 2026

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 27, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this extension study is to evaluate maintenance of Hidradenitis Suppurativa Clinical Response (HiSCR response) in either continuous or interrupted therapy (using a randomized withdrawal period) of two dose regimens and to assess long-term efficacy, safety and tolerability of Secukinumab in subjects with moderate to severe hidradenitis suppurativa completing either of the 2 Phase III studies. This is an expanded access trial for the core trials CAIN457M2301 (NCT03713619) and CAIN457M2302 (NCT03713619).

Conditions

  • Hidradenitis Suppurativa

Interventions

  • secukinumabDrug

    secukinumab 300mg every 2 weeks

  • secukinumabDrug

    secukinumab 300mg every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) RespondersTime frame: Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.
  2. Incidence Rate of Participants Achieving Loss of Response (LOR) up to Week 104 in Hidradenitis Suppurativa Clinical Response (HiSCR) RespondersTime frame: Up to 52 weeks: from randomization at the extension study (Week 52) up to Week 104 or loss of response. Study day is defined with respect to the core studies.

Locations

191 sites in 38 countries. Site status is shown where the registry gives one.

  • Northwest Arkansas Center

    Rogers, Arkansas

  • MedDerm Associates

    San Diego, California

  • University Clinical Trials

    San Diego, California

  • Southern California Skin and Laser

    Whittier, California

  • Florida Academic Centers Research and Education LLC

    Coral Gables, Florida

  • University of MiamiHealth System

    Miami, Florida

  • Olympian Clinical Research

    Tampa, Florida

  • University Of South Florida

    Tampa, Florida

  • Advanced Medical Research

    Sandy Springs, Georgia

  • Endeavor Health

    Glenview, Illinois

  • Dundee Dermatology

    West Dundee, Illinois

  • Dawes Fretzin Clinical Rea Group

    Indianapolis, Indiana

  • Tufts Medical Center

    Boston, Massachusetts

  • Beth Israel Deaconess Med Center

    Boston, Massachusetts

  • Minnesota Clinical Study Center

    New Brighton, Minnesota

  • MediSearch Clinical Trials

    Saint Joseph, Missouri

  • St Louis U Clinical Trials

    St Louis, Missouri

  • WA Uni School Of Med

    St Louis, Missouri

  • Skin Specialists PC

    Omaha, Nebraska

  • Icahn School Of Med At Mount Sinai

    New York, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • Wright State University

    Fairborn, Ohio

  • UP Medical Center H System

    Pittsburgh, Pennsylvania

  • Clinical Research Ctr of Carolinas

    Charleston, South Carolina

  • Bellaire Dermatology Associates

    Bellaire, Texas

  • MDRI Baylor University

    Dallas, Texas

  • Austin Inst for Clinical Research

    Pflugerville, Texas

  • Dr. Stephen Miller, MDPA

    San Antonio, Texas

  • Virginia Clinical Research

    Norfolk, Virginia

  • Novartis Investigative Site

    Caba, Argentina

  • Novartis Investigative Site

    Capital Federal, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    La Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Phillip, Australian Capital Territory, Australia

  • Novartis Investigative Site

    Benowa, Queensland, Australia

  • Novartis Investigative Site

    East Melbourne, Victoria, Australia

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Vienna, Austria

Showing 40 of 191 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.